Metagenomi Therapeutics (MGX) Research & Development (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Research & Development for 4 consecutive years, with $22.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development changed 0.02% year-over-year to $22.5 million in Q2 2026; TTM through Jun 2026 was $88.6 million, a 8.73% decrease from a year earlier, with the FY2025 full-year figure at $94.4 million, down 13.51% from the prior year.
• Research & Development was $22.5 million for Q2 2026 at Metagenomi Therapeutics, up from $19.3 million in the prior quarter.
• Over five years, Research & Development peaked at $31.4 million in Q1 2024 and troughed at $19.3 million in Q1 2026.
• A 4-year average of $24.3 million and a median of $24.0 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 56.18% in 2024 and fell 23.24% in 2026, its largest moves.
• Over 4 years, Research & Development stood at $24.8 million in 2023, then declined by 6.43% to $23.2 million in 2024, then declined by 7.18% to $21.5 million in 2025, then advanced by 4.7% to $22.5 million in 2026.
• The last three Research & Development figures came in at $22.5 million (Q2 2026), $19.3 million (Q1 2026), and $21.5 million (Q4 2025), per Business Quant data.